This study aimed to assess whether using GLP-1 RAs before MBS affects weight loss and improvements in obesity-related conditions over three years, in patients who switched to surgery due to an suboptimal response to GLP-1 therapy. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.